460 related articles for article (PubMed ID: 15277403)
21. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.
Kotronen A; Juurinen L; Tiikkainen M; Vehkavaara S; Yki-Järvinen H
Gastroenterology; 2008 Jul; 135(1):122-30. PubMed ID: 18474251
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
[TBL] [Abstract][Full Text] [Related]
23. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
24. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.
Tan GD; Debard C; Funahashi T; Humphreys SM; Matsuzawa Y; Frayn KN; Karpe F; Vidal H
Diabetologia; 2005 Aug; 48(8):1585-9. PubMed ID: 15991021
[TBL] [Abstract][Full Text] [Related]
25. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
26. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
27. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
28. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
Carey DG; Cowin GJ; Galloway GJ; Jones NP; Richards JC; Biswas N; Doddrell DM
Obes Res; 2002 Oct; 10(10):1008-15. PubMed ID: 12376581
[TBL] [Abstract][Full Text] [Related]
29. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
30. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
31. [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance].
Zhao WH; Xiao JZ; Yang WY; Wang N; Wang X; Chen XP; Bu S
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3074-8. PubMed ID: 16324411
[TBL] [Abstract][Full Text] [Related]
32. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
33. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
34. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
Sahin M; Tutuncu NB; Ertugrul D; Tanaci N; Guvener ND
J Diabetes Complications; 2007; 21(2):118-23. PubMed ID: 17331860
[TBL] [Abstract][Full Text] [Related]
35. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
[TBL] [Abstract][Full Text] [Related]
36. Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism.
Yang S; Luo T; Zhou H; Lv Q; Liu L; Zhang W; Gao R; Chen S; Xia W; Luo M; Cheng Q; Li Q
Endocrinology; 2014 Mar; 155(3):941-50. PubMed ID: 24424059
[TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.
Muhlhausler BS; Morrison JL; McMillen IC
Endocrinology; 2009 Sep; 150(9):4287-94. PubMed ID: 19520784
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Seufert J; Lübben G; Dietrich K; Bates PC
Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
[TBL] [Abstract][Full Text] [Related]
39. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
van Wijk JP; de Koning EJ; Cabezas MC; op't Roodt J; Joven J; Rabelink TJ; Hoepelman AI
Ann Intern Med; 2005 Sep; 143(5):337-46. PubMed ID: 16144892
[TBL] [Abstract][Full Text] [Related]
40. Effects of insulin-sensitising agents in mice with hepatic insulin resistance.
Cohen SE; Tseng YH; Michael MD; Kahn CR
Diabetologia; 2004 Mar; 47(3):407-411. PubMed ID: 14730378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
